Belpointe Asset Management’s Virtus Biotech ETF BBP Stock Holding History

Belpointe Asset Management’s Portfolio BBP Stock Details BBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-46	Closed	-$2.27K	–	842
2023 Q1	$2.27K	Hold	46	–	–	﹤0.01%	3275
2022 Q4	$2.27K	Buy	+46	New	+$2.2K	﹤0.01%	3217

Other funds holding BBP

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FEM

Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LCGC

Legacy Capital Group California Los Gatos, California $332M AUM 42.15% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

DSC

Duncker Streett & Co St. Louis, Missouri $591M AUM 26.48% 1-Year Est. Return

Belpointe Asset Management's BBP Position: Q2 2023 in Review

Belpointe Asset Management sold out of Virtus Biotech ETF (BBP) in Q2 2023, closing a stake of 46 shares — an estimated $2.27K sold.

Belpointe Asset Management first reported a position in BBP in Q4 2022 and held it in 2 quarters. The position peaked at $2.27K in Q1 2023. 13 funds tracked by Wall St. Rank hold BBP as of Q2 2023.

Belpointe Asset Management reported no remaining Virtus Biotech ETF position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 46 Virtus Biotech ETF shares in Q2 2023, an estimated $2.27K.
Belpointe Asset Management first reported a position in Virtus Biotech ETF in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Virtus Biotech ETF position peaked at $2.27K in Q1 2023.
13 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.